Du W - Search Results

1

Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.

Vaishampayan U, Flaherty L, Du W, Hussain M. Vaishampayan U, et al. Among authors: du w. Cancer. 2001 Aug 1;92(3):519-23. doi: 10.1002/1097-0142(20010801)92:3<519::aid-cncr1350>3.0.co;2-#. Cancer. 2001. PMID: 11505395 Clinical Trial.

2

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.

Vaishampayan U, Fontana J, Du W, Hussain M. Vaishampayan U, et al. Among authors: du w. Urology. 2002 Dec;60(6):1050-4. doi: 10.1016/s0090-4295(02)01990-8. Urology. 2002. PMID: 12475668 Clinical Trial.

3

Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma.

Vaishampayan U, Fontana J, Du W, Hussain M. Vaishampayan U, et al. Among authors: du w. Am J Clin Oncol. 2004 Dec;27(6):550-4. doi: 10.1097/01.coc.0000135922.12198.e4. Am J Clin Oncol. 2004. PMID: 15577431 Clinical Trial.

4

Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.

Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J. Hussain M, et al. Among authors: du w. Cancer. 1999 Dec 1;86(11):2364-9. Cancer. 1999. PMID: 10590379 Clinical Trial.

5

Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.

Trivedi C, Redman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK, Hussain M. Trivedi C, et al. Among authors: du w. Cancer. 2000 Jul 15;89(2):431-6. doi: 10.1002/1097-0142(20000715)89:2<431::aid-cncr31>3.0.co;2-b. Cancer. 2000. PMID: 10918176 Clinical Trial.

6

Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.

Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M. Vaishampayan U, et al. Among authors: du w. Clin Cancer Res. 2000 Nov;6(11):4205-8. Clin Cancer Res. 2000. PMID: 11106233 Clinical Trial.

7

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.

Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Hussain M, et al. Among authors: du w. J Clin Oncol. 2001 May 1;19(9):2527-33. doi: 10.1200/JCO.2001.19.9.2527. J Clin Oncol. 2001. PMID: 11331332

8

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.

Redman BG, Smith DC, Flaherty L, Du W, Hussain M. Redman BG, et al. Among authors: du w. J Clin Oncol. 1998 May;16(5):1844-8. doi: 10.1200/JCO.1998.16.5.1844. J Clin Oncol. 1998. PMID: 9586899 Clinical Trial.

9

Outcome of relapsed non-Hodgkin's lymphoma patients after allogeneic and autologous transplantation.

Vaishampayan U, Karanes C, Du W, Varterasian M, al-Katib A. Vaishampayan U, et al. Among authors: du w. Cancer Invest. 2002;20(3):303-10. doi: 10.1081/cnv-120001174. Cancer Invest. 2002. PMID: 12025224

10

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.

Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana J, Sakr W, Wood D. Hussain M, et al. Among authors: du w. Urology. 2003 Apr;61(4):774-80. doi: 10.1016/s0090-4295(02)02519-0. Urology. 2003. PMID: 12670564 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,197 results

Search Page

Filters